Crossmark

Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection

Published Online: 2021-10-20

Published Print: 2022-01

Authors

Vitiello, Antonio https://orcid.org/0000-0003-2623-166X
Ferrara, Francesco https://orcid.org/0000-0001-9298-6783
License Information

Text and Data Mining valid from 2021-10-20

Version of Record valid from 2021-10-20
More Information

Article History

Received: 28 June 2021

Accepted: 12 October 2021

First Online: 20 October 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors consent to the publication of the manuscript.

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current